Medpace Holdings, Inc. announced robust financial results for the fourth quarter and full year ended December 31, 2025. The company reported a 32.0% increase in revenue to $708.5 million for Q4 2025, with GAAP net income rising to $135.1 million, or $4.67 per diluted share. Net new business awards also saw a substantial increase of 39.1%, leading to a net book-to-bill ratio of 1.04x.

Medpace delivered a solid Q3 2025 performance, achieving over $659 million in revenue and $111 million in net income, driven by robust new business awards and continued operational efficiency.

Medpace delivered strong revenue growth and steady profitability in Q2 2025, driven by robust new business awards and healthy backlog conversion.

Medpace delivered strong financial results in Q1 2025 with revenue reaching $558.6 million and net income at $114.6 million. However, the company experienced a decline in net new business awards, reflecting a softer demand environment compared to the prior year.

Medpace Holdings, Inc. reported a strong Q4 2024 with revenue growth of 7.7% YoY to $536.6 million. Net income increased significantly to $117.0 million, with diluted EPS of $3.67. The company's backlog increased slightly, while net new business awards saw a decline of 13.8%. EBITDA rose by 39.3% to $133.5 million, with an EBITDA margin of 24.9%.

Medpace Holdings, Inc. reported an 8.3% increase in revenue for the third quarter of 2024, reaching $533.3 million. Net income rose to $96.4 million, or $3.01 per diluted share, and EBITDA increased by 31.7% to $118.8 million.

Medpace Holdings, Inc. reported a revenue increase of 14.6% to $528.1 million for Q2 2024. GAAP net income rose to $88.4 million, or $2.75 per diluted share, compared to $61.1 million, or $1.93 per diluted share, in the same period last year. Net new business awards were $551.0 million, resulting in a book-to-bill ratio of 1.04x. The company forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion.

Medpace Holdings, Inc. reported a strong first quarter in 2024, with revenue increasing by 17.7% to $511.0 million. Net new business awards rose by 10.8% to $615.6 million, resulting in a book-to-bill ratio of 1.20x. GAAP net income increased to $102.6 million, or $3.20 per diluted share.

Medpace Holdings, Inc. reported a strong fourth quarter in 2023, with a 26.5% increase in revenue to $498.4 million and a 26.7% increase in net new business awards to $614.7 million. GAAP net income increased to $78.3 million, or $2.46 per diluted share. The company's backlog as of December 31, 2023, was $2,813.0 million, representing a 20.2% increase.

Medpace Holdings, Inc. announced its financial results for the third quarter ended September 30, 2023, with revenue of $492.5 million, a 28.3% increase compared to the prior-year period. Net new business awards increased by 29.9% to $611.5 million, resulting in a net book-to-bill ratio of 1.24x. GAAP net income was $70.6 million, or $2.22 per diluted share.

Medpace Holdings, Inc. reported a strong second quarter in 2023, with a 31.2% increase in revenue to $460.9 million compared to the previous year. Net new business awards increased by 27.6% to $574.8 million, resulting in a net book-to-bill ratio of 1.25x. GAAP net income rose to $61.1 million, or $1.93 per diluted share.

Medpace Holdings, Inc. reported a strong first quarter in 2023, with revenue increasing by 31.2% to $434.1 million and net new business awards rising by 31.4% to $555.8 million. GAAP net income also saw an increase to $72.9 million, or $2.27 per diluted share.

Medpace Holdings, Inc. announced its Q4 and full year 2022 financial results, with revenue reaching $394.1 million, a 27.7% increase from the previous year. Net new business awards totaled $485.1 million, up 5.8% year-over-year, resulting in a net book-to-bill ratio of 1.23x. GAAP net income was $68.7 million, or $2.12 per diluted share, compared to $50.0 million, or $1.32 per diluted share, in the prior year.

Medpace Holdings, Inc. reported a 29.8% increase in revenue to $383.7 million for the third quarter of 2022, compared to $295.6 million for the comparable prior-year period. GAAP net income increased to $66.0 million, or $2.05 per diluted share, versus $48.6 million, or $1.29 per diluted share, for the comparable prior-year period. Net new business awards were $470.9 million, representing a net book-to-bill ratio of 1.23x.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2022, featuring a 26.2% increase in revenue to $351.2 million, net new business awards of $450.6 million, and GAAP net income of $49.4 million, or $1.46 per diluted share.

Medpace Holdings, Inc. reported a strong first quarter in 2022, with a 27.3% increase in revenue to $330.9 million compared to the prior year. Net new business awards increased by 18.8% to $423.0 million, and GAAP net income rose to $61.3 million, or $1.69 per diluted share.

Medpace Holdings, Inc. announced its Q4 and full year 2021 financial results, with Q4 revenue reaching $308.6 million, an 18.8% increase year-over-year, and net new business awards totaling $458.7 million, up 27.9% from the previous year. GAAP net income for Q4 was $50.0 million, or $1.32 per diluted share. The company provided financial guidance for 2022, forecasting revenue between $1.400 billion and $1.460 billion.

Medpace Holdings, Inc. announced strong third-quarter results with a 28.3% increase in revenue to $295.6 million and a 29.4% increase in net new business awards to $408.0 million. GAAP net income rose to $48.6 million, or $1.29 per diluted share.

Medpace Holdings, Inc. reported a strong second quarter in 2021, with revenue increasing by 35.8% to $278.3 million compared to the prior-year period. Net new business awards grew by 52.5% to $387.6 million, resulting in a net book-to-bill ratio of 1.39x. GAAP net income increased to $39.9 million, or $1.06 per diluted share, compared to $24.1 million, or $0.64 per diluted share, in the prior-year period.

Medpace Holdings, Inc. announced financial results for the first quarter ended March 31, 2021. Revenue increased by 12.6% to $260.0 million compared to the prior-year period. Net new business awards were $356.2 million, and GAAP net income was $43.3 million, or $1.14 per diluted share.

Medpace Holdings, Inc. announced financial results for the fourth quarter and full year ended December 31, 2020. Revenue for the quarter increased by 13.0% to $259.7 million, and net new business awards increased by 27.6% to $358.6 million, resulting in a net book-to-bill ratio of 1.38x. GAAP net income for the quarter was $50.9 million, or $1.35 per diluted share. The company forecasts 2021 revenue in the range of $1.075 billion to $1.175 billion.

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2020. Revenue increased by 6.5% to $230.4 million compared to the prior-year period. Net new business awards were $315.4 million, and GAAP net income was $41.5 million, or $1.09 per diluted share.

Medpace Holdings, Inc. reported a decrease in revenue for the second quarter of 2020, with a corresponding decrease in net income compared to the same period in 2019. However, the company's backlog experienced growth, and net new business awards were significant, resulting in a book-to-bill ratio above 1.

Medpace Holdings, Inc. announced financial results for the first quarter ended March 31, 2020. Revenue increased by 15.0% to $230.9 million compared to the prior-year period. GAAP net income was $29.0 million, or $0.76 per diluted share, versus GAAP net income of $19.2 million, or $0.51 per diluted share, for the first quarter of 2019.

Medpace Holdings, Inc. announced financial results for the fourth quarter and full year ended December 31, 2019. Revenue for the quarter increased by 19.7% to $229.9 million, and net new business awards increased by 21.6% to $281.1 million.